Wednesday, April 24, 2013

The Food and Drug Administration's responsibilities continue to “outstrip” available resources, FDA Commissioner Margaret A. Hamburg said April 23 at the annual conference of the Food and Drug Law Institute.
“Having adequate resources remains a constant concern,” she said.
Hamburg said the agency will lose $209 million this year due to sequestration. Under sequestration, industry user fees also will remain in the Treasury and cannot be used, she said.
Additionally, she said the majority of FDA's budget increase in President Obama's budget request for fiscal year 2014 comes mostly from “enhanced” industry user fees.

“Having adequate resources remains a constant concern.”

--FDA Commissioner Margaret A. Hamburg

The Obama administration's FY 2014 budget proposal, released April 10, seeks $2.6 billion in budget authority and $4.7 billion in total program resources for FDA (70 HCDR, 4/11/13).
The overall FY 2014 request is $821 million, or 21 percent, above the 2012 enacted level, according to the budget proposal. Of the $821 million increase, only $52 million is from budget authority. Industry user fees would fund 94 percent of the proposed budget increase.
New Responsibilities Under FDASIA
Hamburg said the Food and Drug Administration Safety and Innovation Act (FDASIA) gave FDA new responsibilities, which, among others, require the agency to speed medical product reviews and reduce drug shortages.
Under FDASIA, FDA also is required to consider patient views on treatments, Hamburg said.
She said FDA is launching a patient network website that is meant to encourage patients to share ideas.
FDA also “has nearly completed an implementation plan” for FDASIA and “you can look for that in the near future,” Hamburg said.
Drug Shortages
Hamburg said the agency has seen some quality lapses in recent years that have caused drug shortages. “Drug shortages have increased fivefold since 2006,” she said.
Hamburg said quality is a major concern for the agency, and quality depends on the companies that manufacture drugs and devices.
“Quality has to be built into products,” she said. “Quality that's built into a product prevents problems.”
Hamburg said, “We've made progress in correcting and heading off drug shortages.” She noted, however, that quality issues continue.
Compounding Pharmacies
Quality issues also caused the recent fungal meningitis outbreak that is linked to 53 deaths, Hamburg said. The outbreak was caused by contaminated drugs produced by a compounding pharmacy.
“This terrible tragedy must be a wake-up call to our nation,” she said.
Hamburg said FDA recently completed a series of inspections of compounding pharmacies and in some facilities found sterility problems and other issues that could cause contamination. For instance, Hamburg said inspectors found that some technicians were handling sterile products with their bare hands.
FDA inspectors “ran into resistance” from some compounding pharmacies, Hamburg said. “These obstacles are not new, and this is why I've asked Congress for additional authorities.”
Under these new authorities, nontraditional compounding would be subject to federal standards, Hamburg said. Traditional compounding pharmacies typically produce a small amount of custom-made medications for consumers who have a prescription. Nontraditional ones manufacture without prescriptions large quantities of drugs that are sometimes shipped over state lines.
Hamburg said under the new authorities, nontraditional compounding pharmacies would be required to report adverse reactions to FDA, and the agency would have clear authority to examine their records.
Hamburg said FDA's current authorities over compounding pharmacies “are limited and lack clarity.”
“New legislation is needed to address safety concerns and to provide a more tailored approach for compounding,” she said.
By Bronwyn Mixter

source found here

No comments: